EUCTR2004-002550-56-CZ进行中（未招募）1 期
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria at enrolment (visit 1):
- •1.Provision of a written informed consent at visit 1
- •2.Men or women who are 18 years of age or older at time of consenting upon visit 1
- •3.Female patients post menopausal, hysterectomized or if of childbearing potential using a reliable method of birth control.
- •4.Diagnosed with type 2 diabetes
- •5.Treated with diet alone or treatment with a single oral anti-diabetic agent or low doses of two oral anti-diabetic agents. All anti-diabetic medications are to be discontinued at visit 1. Treatment with lipid lowering medication, including statins, must be discontinued at visit 1.
- •Inclusion criteria at placebo run-in (visit 2, lab values from visit 1):
- •6.For patients <30 years old C-peptide concentrations have to be >0.8 ng/mL, 0.26 nmol/L
- •7.HbA1c equal to or over 7 % for patients not on any anti-diabetic drug for 12 weeks prior to visit 1. No lower HbA1c-limit for patients treated with oral anti-diabetic drug(s) within 12 weeks prior to visit 1.
- •8.HbA1c equal to or lower then 10%
- •9.FPG equal to or lower then 13.3 mmol/L, 240 mg/dL
- •10.HDL-C equal to or lower then 40 mg/dL (equal to or lower then 1.03 mmol/L) for males and equal to or lower then 50 mg/dL (1.29 mmol/L) for females
- •Inclusion criteria at randomisation (visit 5, lab values from visit 3 and 4):
- •11.HbA1c equal to or higher then 7 % for patients not on any anti-diabetic drug for 12 weeks prior to visit 1. No lower HbA1c-limit for patients treated with oral anti-diabetic drug(s) within 12 weeks prior to visit 1.
- •12.HbA1c equal to or lower then 10%
- •13.Mean FPG from two measurements (lab values from visit 3 and 4) £13.3 mmol/L, 240 mg/dL
- •14.HDL-C equal to or lower then 40 mg/dL (1.03 mmol/L) for males and equal to or lower then 50 mg/dL (1.29 mmol/L) for females
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Type 1 diabetes, history of diabetic ketoacidosis, or corticosteroid-induced type 2 diabetes
- •2.Active arterial disease such as unstable angina, myocardial infarction, transient ischaemic attack, cerebrovascular accident, myocardial or peripheral vascular disease, revascularization or angioplasty within 24 weeks prior to visit 1
- •3.NYHA heart failure Class III or IV, or unstable Class I or II as judged by the investigator. For definitions see Appendix F.
- •4.History of thyroid ophthalmopathy
- •5.History of malignancy within the last 5 years, excluding successful treatment of basal or squamous cell skin carcinoma
- •6.History of blood lipid induced eruptive xanthomas or hypertriglyceridaemia induced pancreatitis
- •7.Pregnant or breastfeeding patients
- •8.Suspicion that the patient is infected according to world health organisation (WHO) risk categories 2 to 4 (See Appendix H)
- •9.Treatment with chronic insulin, within 24 weeks prior to visit 1 (however, one temporary period of daily insulin injections no longer than 7 days is allowed)
- •10.Treatment with combination therapy (i.e. two anti diabetic agents, except low doses of two agents, see Section 3.7) within 12 weeks prior to visit 1
- •11.Treatment with a thiazolidinedione within 4 weeks prior to visit 1
- •12.Treatment with fibrates, within 4 weeks prior to visit 1
- •13.Treatment with glucocorticoids (equivalent to oral prednisolon >10 mg per day), within 4 weeks prior to visit 1
- •14.Treatment with probenecid that cannot be stopped at visit 1
- •15.History of hypersensitivity or intolerance to any PPAR agonist
- •16.Pre-existing medical conditions that is contraindicated for the use of fenofibrate
- •17.Intolerance to metformin at any time in the past, or pre-existing medical conditions that is contraindicated for the use of metformin
- •18.Intolerance to an HMG-CoA reductase inhibitor (statin) at any time in the past, or pre-existing medical conditions that is contraindicated for the use of statins
- •19.History of drug-induced myopathy or drug-induced CK elevation
- •20.History of drug-induced liver enzyme elevations
- •21.History of drug-induced neutropenia
- •22.History of alcohol or drug abuse within the last 5 years
- •23.Other serious or unstable medical or psychological condition identified in the patient’s medical history that, in the judgement of the investigator, would compromise the patient’s safety or successful participation in the Clinical Study
- •24.Receiving any investigational product in other clinical studies within 12 weeks prior to visit 1
- •25.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site)
- •26.Previous enrolment or randomisation of treatment in the present study
- •Exclusion criteria at run-in (visit 2, lab values from visit 1)
- •27.Any clinically significant abnormality identified on physical examination, laboratory tests or ECG, which in the judgement of the investigator would compromise the patient’s safety or successful participation in the study
- •28.NYHA heart failure Class III or IV, or unstable Class I or II as judged by the investigator. For definitions see Appendix F.
- •29.Fasting TG >7.0 mmol/L, 620 mg/dL
- •30.Hb <90 g/L, 9 g/dL
- •31.ANC <1.0 x 109/L
- •32.Any of alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) >2.5 times the upper limit of normal
- •33.Total bilirubin above the upper limit of normal unless exclusively caused by Gilbert’s syndrome
- •34.Creatinine above the upper limit of normal
研究者
相似试验
进行中（未招募）
不适用
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemiaie low HDL-C.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-002550-56-DEAstraZeneca AB1,000
进行中（未招募）
不适用
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemiaie low HDL-C.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-002550-56-FIAstraZeneca AB1,000
进行中（未招募）
不适用
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin. - GALLANT 14Men or women diagnosed with type 2 diabetes and treated with diet alone or on treatment with a single oral anti diabetic agent or low doses of two agents, and with diabetic dyslipidaemiaie low HDL-C.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-002550-56-HUAstraZeneca AB1,000
进行中（未招募）
不适用
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered as Monotherapy to Drug-Naïve Patients with Type 2 Diabetes - GALLANT 22Men or women who are 18 years of age or more at enrolment (visit 1). The patients should be drug-naïve with Type 2 diabetes and not on anti-diabetic treatment during the recent 24 weeks.MedDRA version: 7Level: LLTClassification code 10045242EUCTR2004-004374-90-EEAstraZeneca AB475
进行中（未招募）
1 期
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Sulphonylurea AloneEUCTR2004-001144-71-ESAstraZeneca AB555